Status post aortic valve replacement with bioprosthetic valve
Conditions
Interventions
Interventions:Livalo(pitavastatin) Period:3-5years medication:livalo 2~4mg/day
control:no medication Period:3-5years
Sponsors
Department of Cardiovascular Surgery, Tohoku University
Tohoku Kosei Nenkin hospital Sendai Open hospital Miyagi Cardiovascular and respiratory center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who underwent AVR operation using bioprosthetic valve.
Exclusion criteria
Exclusion criteria: hyperlipidemia coronary artery disease malignancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcomes: Velocity and pressure gradient of bioprosthetic aortic valve (6, 12, 24, 36 months after AVR) | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes: Calcification score (Agatston score) of bioprosthetic aortic valve (24months after AVR) | — |
Countries
Japan
Contacts
Public ContactKumagai Kiichiro
Tohoku University Research Division of Sciences for Aortic Disease
Outcome results
None listed